PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
January 28, 2019Harm Reduction Journal132 citationsOpen Access

Medical cannabis patterns of use and substitution for opioids results from a cross-sectional survey of authorized patients

View Full Paper
PLPhilippe LucasEBEric P. BaronNJNick Jikomes

Key Points

Key points are not available for this paper at this time.

Abstract

BACKGROUND: A 239-question cross-sectional survey was sent out via email in January 2017 to gather comprehensive information on cannabis use from Canadian medical cannabis patients registered with a federally authorized licensed cannabis producer, resulting in 2032 complete surveys. METHODS: The survey gathered detailed demographic data and comprehensive information on patient patterns of medical cannabis use, including questions assessing the self-reported impact of cannabis on the use of prescription drugs, illicit substances, alcohol, and tobacco. RESULTS: Participants were 62.6% male (n = 1271) and 91% Caucasian (n = 1839). The mean age was 40 years old, and pain and mental health conditions accounted for 83.7% of all respondents (n = 1700). Then, 74.6% of respondents reported daily cannabis use (n = 1515) and mean amount used per day was 1.5 g. The most commonly cited substitution was for prescription drugs (69.1%, n = 953), followed by alcohol (44.5%, n = 515), tobacco (31.1%, n = 406), and illicit substances (26.6%, n = 136). Opioid medications accounted for 35.3% of all prescription drug substitution (n = 610), followed by antidepressants (21.5%, n = 371). Of the 610 mentions of specific opioid medications, patients report total cessation of use of 59.3% (n = 362). CONCLUSIONS: This study offers a unique perspective by focusing on the use of a standardized, government-regulated source of medical cannabis by patients registered in Canada's federal medical cannabis program. The findings provide a granular view of patient patterns of medical cannabis use, and the subsequent self-reported impacts on the use of opioids, alcohol, and other substances, adding to a growing body of academic research suggesting that increased regulated access to medical and recreational cannabis can result in a reduction in the use of and subsequent harms associated with opioids, alcohol, tobacco, and other substances.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Lucas et al. (2019) studied this question.

synapsesocial.com/papers/6a626a334cf9e5f8a6c21848https://doi.org/10.1186/s12954-019-0278-6
Ask AI
Helpful
Bookmark
Share
View Full Paper

Also Consider

Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Maternal Marijuana Use and Adverse Neonatal Outcomes2016 · 289 citations
  2. 2Acute cannabis consumption and motor vehicle collision risk: systematic review of observational studies and meta-analysis2012 · 743 citations
  3. 3Joint Effects: A Pilot Investigation of the Impact of Bipolar Disorder and Marijuana Use on Cognitive Function and Mood2016 · 33 citations
  4. 4Substituting cannabis for prescription drugs, alcohol and other substances among medical cannabis patients: The impact of contextual factors2015 · 156 citations